Loading...
XSTOORX
Market cap55mUSD
Dec 23, Last price  
17.80SEK
1D
-7.58%
1Q
28.06%
Jan 2017
-52.66%
IPO
-80.21%
Name

Orexo AB

Chart & Performance

D1W1MN
XSTO:ORX chart
P/E
—
P/S
0.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.39%
Rev. gr., 5y
-3.99%
Revenues
639m
+2.32%
86,715,00062,352,000131,956,0000233,346,000236,104,000210,499,000199,614,000326,278,000429,355,000570,316,000643,338,000705,800,000643,700,000783,100,000844,800,000663,600,000565,000,000624,300,000638,800,000
Net income
-128m
L-27.76%
-15,944,000-43,249,000-32,943,0000-103,054,000-98,079,000-89,246,000-392,009,000-85,863,000-154,936,000-56,584,000-197,987,00029,000,00023,200,000137,900,000219,100,000-84,400,000-223,500,000-177,600,000-128,300,000
CFO
-95m
L-39.34%
-15,944,000-45,382,000-25,279,000-160,485,000-101,490,000-133,927,000-42,967,000-117,228,00028,668,000-263,201,000-487,300,000-102,193,000156,200,000146,600,000242,000,000287,000,00016,800,000-229,000,000-156,600,000-95,000,000
Earnings
Feb 06, 2025

Profile

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
URL
https://orexo.se/
IPO date
Nov 09, 2005
Employees
120
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
638,800
2.32%
624,300
10.50%
565,000
-14.86%
Cost of revenue
761,500
821,900
783,100
Unusual Expense (Income)
NOPBT
(122,700)
(197,600)
(218,100)
NOPBT Margin
Operating Taxes
(12,000)
7,200
1,000
Tax Rate
NOPAT
(110,700)
(204,800)
(219,100)
Net income
(128,300)
-27.76%
(177,600)
-20.54%
(223,500)
164.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
20,900
20,600
20,200
Long-term debt
478,300
563,800
588,500
Deferred revenue
Other long-term liabilities
11,600
10,200
13,600
Net debt
328,200
451,300
103,800
Cash flow
Cash from operating activities
(95,000)
(156,600)
(229,000)
CAPEX
(18,500)
(23,900)
(52,800)
Cash from investing activities
200,800
(234,700)
(52,900)
Cash from financing activities
(70,100)
(21,400)
250,600
FCF
(125,600)
(218,700)
(230,600)
Balance
Cash
171,000
351,800
504,100
Long term investments
(218,700)
800
Excess cash
139,060
101,885
476,650
Stockholders' equity
(1,757,000)
(1,622,000)
(1,466,000)
Invested Capital
2,301,300
2,361,400
2,375,800
ROIC
ROCE
EV
Common stock shares outstanding
34,413
34,352
34,320
Price
15.46
-18.03%
18.86
-45.33%
34.50
-31.00%
Market cap
532,031
-17.88%
647,874
-45.28%
1,184,028
-31.16%
EV
860,231
1,099,174
1,288,228
EBITDA
(45,600)
(128,900)
(165,100)
EV/EBITDA
Interest
41,200
27,800
28,200
Interest/NOPBT